<DOC>
	<DOC>NCT00422227</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy of etanercept with usual disease-modifying anti-rheumatic drug (DMARD) therapy in the treatment of moderate to severe rheumatoid arthritis (RA) over 16 weeks in the Asia Pacific region.</brief_summary>
	<brief_title>Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>Diagnosis of RA Currently receiving an adequate dose of methotrexate (MTX) for treatment of RA Active RA at time of screening and baseline Previous or current treatment with etanercept (ETN), other tumor necrosis factoralpha inhibitors, or other biologic agents Concurrent treatment with a DMARD, other than MTX, at screening Receipt of any DMARD, other than MTX, within 3 months before screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>